Page last updated: 2024-08-17

triiodothyronine and esmolol

triiodothyronine has been researched along with esmolol in 4 studies

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (25.00)29.6817
2010's3 (75.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Christ, M; Feuring, M; Georgens, AC; Martin, N; Schmidt, BM; Tillmann, HC; Wehling, M1
Burman, KD; Carroll, NM; Devdhar, M; Popoveniuc, G; Sharma, M; Wartofsky, L; Wexler, JA1

Reviews

1 review(s) available for triiodothyronine and esmolol

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016

Trials

1 trial(s) available for triiodothyronine and esmolol

ArticleYear
Nongenomic cardiovascular effects of triiodothyronine in euthyroid male volunteers.
    The Journal of clinical endocrinology and metabolism, 2002, Volume: 87, Issue:4

    Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Adult; Cardiac Output; Cardiography, Impedance; Cardiovascular System; Cross-Over Studies; Diagnosis, Computer-Assisted; Dobutamine; Double-Blind Method; Electrocardiography; Heart Rate; Humans; Male; Propanolamines; Reference Values; Triiodothyronine; Vascular Resistance

2002

Other Studies

2 other study(ies) available for triiodothyronine and esmolol

ArticleYear
FDA-approved drug labeling for the study of drug-induced liver injury.
    Drug discovery today, 2011, Volume: 16, Issue:15-16

    Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration

2011
Graves' disease and thymic hyperplasia: the relationship of thymic volume to thyroid function.
    Thyroid : official journal of the American Thyroid Association, 2010, Volume: 20, Issue:9

    Topics: Adrenergic beta-Antagonists; Adult; Anti-Inflammatory Agents; Antithyroid Agents; Calcium Channel Blockers; Diltiazem; Female; Graves Disease; Humans; Male; Methimazole; Middle Aged; Organ Size; Prednisone; Propanolamines; Propranolol; Radiography; Thymus Gland; Thymus Hyperplasia; Thyroidectomy; Thyrotoxicosis; Thyrotropin; Thyroxine; Treatment Outcome; Triiodothyronine; Young Adult

2010